Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

British Journal of Cancer

Volumn 109, Issue 7, 2013, Pages 1904-1907

  Nouso, K ^a   Miyahara, K ^a   Uchida, D ^a   Kuwaki, K ^a   Izumi, N ^b   Omata, M ^c   Ichida, T ^d   Kudo, M ^e   Ku, Y ^f   Kokudo, N ^g   Sakamoto, M ^h   Nakashima, O ⁱ   Takayama, T ^j   Matsui, O ^k   Matsuyama, Y ^l   Yamamoto, K ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c Yamanashi Prefectural Hospital Organization   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KANAZAWA UNIVERSITY   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

5 fluorouracil; chemotherapy; cisplatin; hepatocellular carcinoma; liver neoplasm; propensity score

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; JAPAN; LIVER NEOPLASMS; MALE; TREATMENT OUTCOME;

EID: 84885176975     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.542     Document Type: Article

References (20)

1. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95(3): 588-595.
2. Austin PC, Mamdani MM (2006) A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 25(12): 2084-2106.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1): 25-34.
4. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC (2009) Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 44(12): 1477-1486.
5. European Organisation for Research and Treatment of Cancer (2012) EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48(5): 599-641.
6. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15): 1869-1883.
7. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Yamaoka Y (2005) Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 32(3): 163-172.
8. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M (2007) Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatology Res 37(9): 676-691.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
10. Kim BK, Park JY, Choi HJ, Kim do Y, Ahn SH, KimJK, Lee do Y, Lee KH, Han KH (2011) Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 137(4): 659-667.
11. Kim do Y, Ahn SH, Kim SU, Choi SB, Lee KH, Park MS, Park JY, Lee do Y, Han KH, Kim KS (2011) Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. Oncology 81(3-4): 184-191.
12. Kim R, Tanabe K, Inoue H, Toge T (2002) Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 20(3): 549-555.
13. Kudo M (2012) Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets 12(9): 1062-1072.
14. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. HCC Expert Panel of Japan Society of Hepatology (2011) Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29(3): 339-364.
15. Liver Cancer Study Group of Japan (2003) General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Second English edition. Kanehara & Co. Ltd: Tokyo.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SIS Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390.
17. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83(23): 8923-8925.
18. Sherman M, Bruix J, Porayko M, Tran T, Committee APG (2012) Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 56(3): 793-796.
19. Ueshima K, KudoM, TakitaM, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H (2010) Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 78(Suppl 1): 148-153.
20. Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S (2011) Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 81(5-6): 281-290.